Interleukin‐6 and interleukin‐17 are related to depression in patients with rheumatoid arthritis

Li, Ya-Chi; Chou, Yu‐Ching; Hc, Chen; Lu, Chun–Chi; Chang, Deh‐Ming

doi:10.1111/1756-185x.13529

Cited by 47 publications

(44 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…No significant differences were found between the values of depression ratings and the IL-6 levels. However, a study in Taiwan with 113 RA patients and 42 healthy controls demonstrated elevated serum IL-6 and IL-17 levels in RA patients with depressive symptoms [74].…”

Section: Il-6 In Physical Diseases Associated With Depressionmentioning

confidence: 96%

Role of Interleukin-6 in Depressive Disorder

Ting

Yang

Tsai

2020

IJMS

223

152

View full text Add to dashboard Cite

Major depressive disorder (MDD), which is a leading psychiatric illness across the world, severely affects quality of life and causes an increased incidence of suicide. Evidence from animal as well as clinical studies have indicated that increased peripheral or central cytokine interleukin-6 (IL-6) levels play an important role in stress reaction and depressive disorder, especially physical disorders comorbid with depression. Increased release of IL-6 in MDD has been found to be a factor associated with MDD prognosis and therapeutic response, and may affect a wide range of depressive symptomatology. However, study results of the IL6 genetic effects in MDD are controversial. Increased IL-6 activity may cause depression through activation of hypothalamic-pituitary-adrenal axis or influence of the neurotransmitter metabolism. The important role of neuroinflammation in MDD pathogenesis has created a new perspective that the combining of blood IL-6 and other depression-related cytokine levels may help to classify MDD biological subtypes, which may allow physicians to identify the optimal treatment for MDD patients. To modulate the IL-6 activity by IL-6-related agents, current antidepressive agents, herb medication, pre-/probiotics or non-pharmacological interventions may hold great promise for the MDD patients with inflammatory features.

show abstract

Section: Il-6 In Physical Diseases Associated With Depressionmentioning

confidence: 96%

Role of Interleukin-6 in Depressive Disorder

Ting

Yang

Tsai

2020

IJMS

223

152

View full text Add to dashboard Cite

show abstract

“…In addition, most RA cases were among people living in rural areas and the loss of labour force caused by disability further worsens the economic situation of these patients, which brings about heavy burden to their families and causes long‐term negative impact on patients. Since systematic autoimmune inflammation caused by RA can increase the risk of depression (Kim, Chanyang, Oh, & Choi, 2019), RA shares similar pathological basis with depression in the aspect of neurological–endocrine–immunological regulatory axis (Li, Y.C., Chou, Chen, Lu, & Chang, 2019; Lopresti, Maker, Hood, & Drummond, 2014; Slavich & Irwin, 2014). Unfortunately, the comorbidity of depression will further exacerbate physical disability and healthcare burden.…”

Section: Introductionmentioning

confidence: 99%

Mapping publication status and exploring hotspots in a research field: Rheumatoid arthritis with depression

Wang

Zhang

et al. 2020

Journal of Advanced Nursing

View full text Add to dashboard Cite

Rheumatoid Arthritis (RA) is a systemic autoimmune disease characterized by the chronic erosive arthritis, which causes a high disability rate (Zhou et al., 2013). The global incidence of RA is 0.5-1% (Smolen, Aletaha, & MeInnes, 2016). The aetiology and pathogenesis of this long-term progressive disease are complex, which may be related to both immune factors and the abnormality of synovial cells. RA is

show abstract

“…Interestingly, there is conflicting evidence about a potential role of IL-17 in depressive states. [29][30][31] The main limitations of this study are its retrospective nature and the relatively small number of observed patients. Moreover, a survivorship bias may emerge as a consequence of the minimum follow-up time of 6 months and could result in a slight underestimation of non-responders.…”

Section: Discussionmentioning

confidence: 97%

Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet’s phenotype: a multicentre study

et al. 2020

View full text Add to dashboard Cite

ObjectiveTo evaluate the effectiveness and safety of secukinumab in patients with a mucosal and articular Behçet’s phenotype resistant to conventional and biologic treatment.MethodsA multicentre retrospective study was performed on 15 patients with a mucosal and articular phenotype of Behçet’s syndrome fulfilling the International Criteria for Behçet’s Disease and refractory to treatment with colchicine, disease-modifying antirheumatic drugs and at least one antitumour necrosis factor-α agent. Minimum follow-up was set at 6 months. Six patients with a polyarticular involvement were treated with secukinumab 300 mg/month, while all other cases received secukinumab 150 mg/month. Dose increase from 150 to 300 mg per month and shortening of administration frequency were allowed for poor disease control. Response evaluation was based on the number of oral ulcers in the previous 28 days and Disease Activity Score-28 for articular manifestations.ResultsAt 3 months of follow-up, nine (66.7%) patients achieved a response (complete or partial), and this proportion further increased to 86.7% at 6 months, 76.9% at 12 months, 90.0% at 18 months and 100.0% after 24 months. Notably, all patients who started with secukinumab 300 mg/month achieved complete response by month 6. Seven (46.7%) patients could achieve a response only after switching to a higher dosage.ConclusionsOur study suggests that secukinumab at a dose of 150 and 300 mg per month is safe and effective for the long-term treatment of patients with Behçet’s syndrome with a mucosal and articular phenotype refractory to previous treatments. Notably, secukinumab 300 mg/month resulted in superior complete mucosal and articular responses with no serious or dose-related adverse effects.

show abstract

Interleukin‐6 and interleukin‐17 are related to depression in patients with rheumatoid arthritis

Abstract: Aim: Mood disorders are a serious issue for patients with rheumatoid arthritis (RA) because poor mental health can exacerbate the disease course. This study aimed to identify the effect of proinflammatory cytokines on the mood of patients with RA.

Cited by 47 publications

References 26 publications

Role of Interleukin-6 in Depressive Disorder

Role of Interleukin-6 in Depressive Disorder

Mapping publication status and exploring hotspots in a research field: Rheumatoid arthritis with depression

Long-term effectiveness and safety of secukinumab for treatment of refractory mucosal and articular Behçet’s phenotype: a multicentre study

Contact Info

Product

Resources

About